Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 603 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: EX Clear all
Recruiting Not applicable Interventional

High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial

NCT06298734
View directory record Official record
Conditions
Melanoma (Skin), Skin Cancer, Advanced Melanoma
Interventions
Exercise Program, Diet Program
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 20, 2026, 3:17 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Resilience in Adolescent Development

NCT03458936
View directory record Official record
Conditions
Risk Assessment, Resilience, Psychological, Depression, Mood Disorders, Anxiety Disorders, Mental Health
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
10 Years to 24 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 20, 2026, 3:17 AM EDT
Not listed Phase 1Phase 2 Interventional

Safety Evaluation of ART352-L in Subjects Undergoing Posterolateral Spinal Fusion

NCT04378543
View directory record Official record
Conditions
Degenerative Spondylolisthesis
Interventions
ART352-L
Biological
Lead sponsor
Ankasa Regenerative Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Rochester, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 20, 2026, 3:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID

NCT02999984
View directory record Official record
Conditions
Severe Combined Immunodeficiency Due to ADA Deficiency
Interventions
Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101), busulfan, PEG-ADA ERT
Genetic · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
30 Days to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 20, 2026, 3:17 AM EDT
Terminated Phase 1 Interventional

Multimodal Imaging Outcome Measures for ALS (Image ALS)

NCT04490096
View directory record Official record
Conditions
ALS
Interventions
[11C]-PBR28
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 20, 2026, 3:17 AM EDT
Terminated No phase listed Observational

Assessing the Induction of Long-term Immune Regulation Following Treatment With Lemtrada® (Alemtuzumab).

NCT03647722
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Assessment of leukocyte function.
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 20, 2026, 3:17 AM EDT
Completed Phase 2 Interventional

Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers

NCT02725489
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Uterine Cancer, Cervical Cancer, Endometrial Cancer
Interventions
Vigil, Durvalumab
Biological · Drug
Lead sponsor
Mary Crowley Medical Research Center
Other
Eligibility
18 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 20, 2026, 3:17 AM EDT
Completed Phase 1 Interventional

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

NCT03941262
View directory record Official record
Conditions
Refractory Cancer, Metastatic Cancer, Recurrent Cancer, Unresectable Carcinoma, Solid Tumor, Adult, Advanced Cancer, Advanced Solid Tumor
Interventions
SNK01, Avelumab, Pembrolizumab
Biological · Drug
Lead sponsor
NKGen Biotech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 20, 2026, 3:17 AM EDT
Completed Not applicable Interventional Results available

Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma

NCT02645409
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
OTL38, Intraoperative fluorescence imaging system
Drug · Device
Lead sponsor
Chandru Sundaram
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Oct 20, 2026, 3:17 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers

NCT00539656
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Leukemia, Bilineage, Acute, Leukemia, Myeloid, Chronic
Interventions
Ex vivo expansion of cord blood
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Oct 20, 2026, 3:17 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease

NCT04476277
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Interventions
Biotin label
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Oct 20, 2026, 3:17 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Vincere Biobank Research Protocol

NCT05954299
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
Vincere Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2038
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 20, 2026, 3:17 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss

NCT01451099
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
6
States / cities
Atlanta, Georgia • Chevy Chase, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Oct 20, 2026, 3:17 AM EDT
Recruiting Phase 4 Interventional

Post-mastectomy Recovery: Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks

NCT06574022
View directory record Official record
Conditions
Mastectomy; Lymphedema, Breast Cancer
Interventions
Bupivacain, Exparel, Intraoperative Pecs II block (IOB) & superior AT (EX or BP), Preoperative Pecs II block (POB) & superior AT (EX or BP)
Drug · Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 20, 2026, 3:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Collaborative Lifestyle Intervention Program in Knee Osteoarthritis Patients

NCT02835326
View directory record Official record
Conditions
Osteoarthritis
Interventions
Exercise and Dietary Weight Loss, Walk with Ease
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
50 Years and older
Enrollment
227 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 20, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Exercise, Milk Thistle, and Lactobacillus to Influence Plasma Bilirubin

NCT04717726
View directory record Official record
Conditions
Obesity
Interventions
Milk Thistle (MT), Lactobacillus Gasseri (LAC), Exercise (EX), Control (CON)
Dietary Supplement · Behavioral
Lead sponsor
Kyle Flack
Other
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 20, 2026, 3:17 AM EDT
Completed Phase 2 Interventional Results available

Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis

NCT03355365
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Intrathecal MSC-NP injection, Intrathecal saline injection
Biological · Other
Lead sponsor
Tisch Multiple Sclerosis Research Center of New York
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Oct 20, 2026, 3:17 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)

NCT02691247
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
CLBS03 Low Dose, CLBS03 High Dose, Placebo
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
8 Years to 17 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 20, 2026, 3:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Quantification of Intramyocardial Lipid by Proton Magnetic Resonance Spectroscopy

NCT00469911
View directory record Official record
Conditions
Heart Transplantation
Interventions
Magnetic Resonance Spectroscopy, Ex vivo heart biopsy
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 20, 2026, 3:17 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma

NCT02040766
View directory record Official record
Conditions
Asthma
Interventions
Beclomethasone dipropionate BAI, Placebo BAI, albuterol/salbutamol 90 mcg, Beclomethasone dipropionate MDI, Placebo MDI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
4 Years to 11 Years
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
75
States / cities
Hoover, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 20, 2026, 3:17 AM EDT
Completed Phase 1 Interventional

Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3

NCT00000756
View directory record Official record
Conditions
HIV Infections
Interventions
Lymphocytes, Activated
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 20, 2026, 3:17 AM EDT
Completed Not applicable Interventional

A Trial of Positively Smoke Free Group Therapy for HIV-infected Smokers

NCT02072772
View directory record Official record
Conditions
Tobacco Use in Persons Living With HIV
Interventions
Positively Smoke Free group treatment, Standard Care
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 20, 2026, 3:17 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

NCT05685004
View directory record Official record
Conditions
Glioblastoma Multiforme of Brain
Interventions
TVI-Brain-1, Standard of Care, Radiotherapy, Temozolomide
Biological · Procedure · Radiation + 1 more
Lead sponsor
TVAX Biomedical
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 3:17 AM EDT
Completed Early Phase 1 Interventional

A Microdose Evaluation Study of ABY-029 in Primary Sarcoma

NCT03154411
View directory record Official record
Conditions
Primary Soft-tissue Sarcoma
Interventions
ABY-029
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 20, 2026, 3:17 AM EDT